Search Results - "Mineur, H."

Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study by Belkacémi, Y., Gligorov, J., Ozsahin, M., Marsiglia, H., De Lafontan, B., Laharie-Mineur, H., Aimard, L., Antoine, E.-C., Cutuli, B., Namer, M., Azria, D.

“…Trastuzumab (T) combined with chemotherapy has been recently shown to improve outcome in HER2-positive breast cancer (BC). The aim of this study was to…”
Get full text

Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer by Taieb, J., Phelip, J.M., Rinaldi, Y., Barbier, E., Bouche, O., Khemissa Akouz, F., Gratet, A., Petorin, C., Miglianico, L., Malka, D., Laharie Mineur, H., Rebischung, C., Lepage, C., Francois, E., Dahan, L.

Get full text

Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer by Belkacémi, Y, Laharie-Mineur, H, Gligorov, J, Azria, D

“…Trastuzumab (Herceptin) is the first humanised monoclonal antibody targeting the HER2 antigen in breast cancer. HER2 receptor has been individualised 20 years…”
Get full text

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial by Kerbrat, Pierre, Fumoleau, Pierre, Jacquin, Jean-Philippe, Abadie-Lacourtoisie, Sophie, Cany, Laurent, Khayat, David, Paget-Bailly, Sophie, Demarchi, F, N'Guyen, T, Stein, U, Villanueva, C, Guimont, I, Lévy, E, Delbaldo, C, Pouessel, D, Fournel-Fédérico, C, Freyer, G, Tartas, S, Bons, F, Cuvier, C, Hajjaji, N, Capitain, O, Maillart, P, Bonnefoi, H, Durand, M, Madranges, N, Mauriac, L, Durando, X, Durieux, A, Piperno-Neumann, S, Tresca, P, Ferrant, E, Mayer, F, Vanneuville, AC, Servent, V, Guastalla, JP, Biron, P, Dupuy-Brousseau, L, Lancry, L, Trédan, O, Extra, JM, Berton-Rigaud, D, Ferrero, JM, Largillier, R, Gedoin, D, Laguerre, B, Lefeuvre, C, Vauléon, E, Tennevet, I, Mefti-Lacheraf, F, Dalenc, F, André, F, Domont, J, Ezenfis, J, Provençal, J, Bellaiche-Miccio, C, Boutan-Laroze, G, Arsène, O, Merad-Boudia, Z, Orfeuvre, H, Lamy, R, Sarda, C, Salles, B, Cauvin, I, Mangold, M, Bourcier, A, Geay, JF, ElAmarti, R, Combe, M, Dauba, J, Denizon, N, Clavreul, G, Goubely, Y, Delecroix, V, Ligeza-Poisson, V, Leyronnas, C, Teissier, E, Bernard, O, Pottier-Kyndt, V, Drony, S, Moriceau, M, Besson, D, Achille, E, Moran-Ribon, A, Moullet, I, Couderc, B, Burki, F, Schaeffer, F, Montcuquet, P, Baumont, GA, Gréget, S, Ratoanina, JL, Bonichon-Lamichhane, M, Cartron, G, Dupuis, O, Ganem, G, LeRol, A, Antoine, EC, Llory, JF, Loiseau, D

“…In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant…”
Get full text

Bénéfice et risques potentiels de l'association du trastuzumab à la chimiothérapie et à la radiothérapie dans le cancer du sein non métastatique by Belkacémi, Y., Laharie-Mineur, H., Gligorov, J., Azria, D.

“…Le trastuzumab (Herceptin ®), un anticorps monoclonal humanisé anti-HER2 ( human epidermal growth factor receptor), est le premier traitement ciblant un…”
Get full text

722PExploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer by Taieb, J, Phelip, J M, Rinaldi, Y, Barbier, E, Bouche, O, Khemissa Akouz, F, Gratet, A, Petorin, C, Miglianico, L, Malka, D, Laharie Mineur, H, Rebischung, C, Lepage, C, Francois, E, Dahan, L

Get full text

Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients by Berton-Rigaud, D., Floquet, A., Mollon-Grange, D., Dechartres, A., Lescaut, W., Kaminsky-Forrett, M.-C., Tredan, O., Largillier, R., Savoye, A.M., Alexandre, J., Delbaldo, C., Malaurie, E., Barletta, H., Bosacki, C., Tixidre, C Garnier, Follana, P., Laharie-Mineur, H., Levaché, C.-B., Pujade-Lauraine, E., Selle, F.

Get full text

1023PUse of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients by Berton-Rigaud, D, Floquet, A, Mollon-Grange, D, Dechartres, A, Lescaut, W, Kaminsky-Forrett, M-C, Tredan, O, Largillier, R, Savoye, A M, Alexandre, J, Delbaldo, C, Malaurie, E, Barletta, H, Bosacki, C, Tixidre, C Garnier, Follana, P, Laharie-Mineur, H, Levaché, C-B, Pujade-Lauraine, E, Selle, F

“…Abstract Background Bevacizumab (bev) is approved in Europe (EU) for first line therapy of OC patients (pts). This study aimed to evaluate the use of Bev in…”
Get full text

1023P - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients by Berton-Rigaud, D., Floquet, A., Mollon-Grange, D., Dechartres, A., Lescaut, W., Kaminsky-Forrett, M.-C., Tredan, O., Largillier, R., Savoye, A.M., Alexandre, J., Delbaldo, C., Malaurie, E., Barletta, H., Bosacki, C., Tixidre, C Garnier, Follana, P., Laharie-Mineur, H., Levaché, C.-B., Pujade-Lauraine, E., Selle, F.

“…Bevacizumab (bev) is approved in Europe (EU) for first line therapy of OC patients (pts). This study aimed to evaluate the use of Bev in real life, with a…”
Get full text

Abstract P3-12-10: First 6-month report of the longitudinal PHACS study ( P harmacology and H ormonotherapy (HT) for A djuvant breast C ancer (BC) S tudy, NCT01127295) by Roché, H, Venat-Bouvet, L, Debled, M, Jacot, W, Suc, E, Dalenc, F, Molnar-Stanciu, D, Dohollou, N, Franck, D, Ferrer, C, Laharie-Mineur, H, Lavau-Denes, S, Massabeau, C, Mauries, V, Robert, J, Pinguet, F, Marquet, P, Evrard, A, Chatelut, E, Filleron, T

“…Background: BC is a hormone-dependent disease for 75% of pts. HT is used in both adjuvant and metastatic settings for hormone–receptor (HR) positive tumors. In…”
Get full text

Robustesse du guidage surfacique en comparaison avec le spiromètre dans la mise en place du blocage respiratoire pour le traitement du cancer du sein by Messina, C., Guibert, A.-L., Martin, G., Chauvet, V., Bonichon-Lamichhane, N., Debelleix, C., Régnault de la Mothe, P., Taupiac, J.P., Mineur, H.

“…Le blocage respiratoire est désormais un standard de traitement pour les cancers du sein gauche dont la mise en œuvre implique typiquement l’utilisation d’un…”
Get full text

OT2-06-01: A Phase III Randomized Multicentric French Study To Evaluate the Impact of a Localized 16-Gy Boost after Conservative Surgery and a 50-Gy Whole-Breast Irradiation in Breast Ductal Carcinoma In Situ (The BONBIS Trial) by Azria, D, Cowen, D, De, La Lande B, Bourgier, C, Latorzeff, I, Leblanc-Onfroy, M, Douadi-Gaci, Z, Pradier, O, Peignaux, K, Levy, C, Ellis, S, Lecouillard, I, Racadot, S, Bontemps, P, Benyoucef, A, Lagarde, P, Laharie-Mineur, H, Cretin, J, Marchal, C, Serin, D, Lemanski, C

“…Background Ductal carcinoma in situ is defined as breast cancer confined to the ducts of the breast without evidence of penetration of the basement membrane…”
Get full text

Phase III randomized French multicentric study to evaluate the impact of a localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast irradiation in breast ductal carcinoma in situ (the BONBIS trial) by Azria, D., Cowen, D., Bourgier, C., de la Lande, B., Gourgou-Bourgade, S., Douadi Gaci, Z., Leblanc-Onfroy, M., Latorzeff, I., Pradier, O., Maingon, P., Lecouillard, I., Bontemps, P., Ellis, S., Levy, C., Benyoucef, A., Racadot, S., Laharie-Mineur, H., Lagarde, P., Marchal, C., Lemanski, C.

“…Abstract only…”
Get full text

Sites de récidives du cancer du canal anal après chimioradiothérapie avec modulation d’intensité : analyse rétrospective multicentrique by Amestoy, F., Antoine, M., Henriques, B., Lipinski, F., Genebes, C., Blouet, A., Celerier, D., Regnault de la Mothe, P., Debelleix, C., Petit, A., Laharie-Mineur, H., Bonichon-Lamichhane, N., Vendrely, V.

“…Analyse des sites de récidives du cancer du canal anal après chimioradiothérapie conformationnelle avec modulation d’intensité (RCMI). Entre septembre 2007 et…”
Get full text

Concurrent administration of weekly trastuzumab and adjuvant breast radiotherapy increases skin, esophageal, and cardiac acute toxicities by Belkacemi, Y., Gligorov, J., Laharie-Mineur, H., Marsiglia, H., Ozsahin, M., Azria, D.

“…Abstract only 630 Background: Trastuzumab (T) combined with chemotherapy (CT) has been recently shown to improve the outcome in patients with HER2-positive…”
Get full text

The Boys and the Barbarians: Some Remarks on Callimachus H. 4, 177 by Mineur, W. H.

Get full text

Carcinomes canalaires in situ bilatéraux : événements indépendants ou maladie bilatérale ? by André, G., Tunon-de-Lara, C., Macgrogan, G., Laharie-Mineur, H., Bussieres, J.-E., Valentin, F., Barreau, B., Dilhuydy, M.-H., Dilhuydy, J.-M., Mauriac, L., Debled, M., Durand, M., Mathoulin, S., Avril, A.

“…Étudier, rétrospectivement des carcinomes canalaires in situ (CCIS) bilatéraux, traités à l'institut Bergonié et rechercher la relation entre les deux…”
Get full text

Prognostic value of Mib1 in a tissue microarray of 855 invasive breast carcinomas by MacGrogan, G., Desrousseaux, M., de Mascarel, I., Mathoulin Pélissier, S., Debled, M., Mauriac, L., Durand, M., Tunon de Lara, C., Laharie Mineur, H., Brouste, V.

Get full text

Ballistocardiographic studies of ethaverine as a coronary vasodilator; preliminary report by MOON, D, MINEUR, H J, HOPPER, G R, SCHWARTZ, S H

Get more information

From Book-Worms To Reed Warblers by Mineur, W.H

Get full text